New hope for rare blood disorder: ruxolitinib trial targets eosinophils
Disease control
Recruiting now
This study tests the drug ruxolitinib in 10 people with hypereosinophilic syndrome or related disorders, where high levels of eosinophils (a type of white blood cell) cause organ damage. The goal is to see if ruxolitinib can lower eosinophil counts and improve symptoms. Participa…
Phase: PHASE2 • Sponsor: William Shomali • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC